MA43869A - Anticorps anti-myl9 - Google Patents

Anticorps anti-myl9

Info

Publication number
MA43869A
MA43869A MA043869A MA43869A MA43869A MA 43869 A MA43869 A MA 43869A MA 043869 A MA043869 A MA 043869A MA 43869 A MA43869 A MA 43869A MA 43869 A MA43869 A MA 43869A
Authority
MA
Morocco
Prior art keywords
myl9
antibodies
myl9 antibodies
Prior art date
Application number
MA043869A
Other languages
English (en)
Inventor
Ryu Gejima
Koji Hayashizaki
Toshifumi Hirayama
Toshio Imai
Jungo Kakuta
Motoko Kimura
Kenzo Muramoto
Toshinori Nakayama
Yoshimasa Sakamoto
Daisuke Tokita
Original Assignee
Eisai R&D Man Co Ltd
Univ Chiba Nat Univ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Univ Chiba Nat Univ Corp filed Critical Eisai R&D Man Co Ltd
Publication of MA43869A publication Critical patent/MA43869A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA043869A 2016-01-12 2017-01-11 Anticorps anti-myl9 MA43869A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016003429 2016-01-12

Publications (1)

Publication Number Publication Date
MA43869A true MA43869A (fr) 2018-11-21

Family

ID=59311587

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043869A MA43869A (fr) 2016-01-12 2017-01-11 Anticorps anti-myl9

Country Status (14)

Country Link
US (1) US10513561B2 (fr)
EP (1) EP3404040B1 (fr)
JP (1) JP6872756B2 (fr)
KR (1) KR102800024B1 (fr)
CN (1) CN108431037B (fr)
AU (1) AU2017207082B2 (fr)
BR (1) BR112018013807A2 (fr)
CA (1) CA3008786A1 (fr)
ES (1) ES2913162T3 (fr)
IL (1) IL260083B2 (fr)
MA (1) MA43869A (fr)
MX (1) MX2018008358A (fr)
RU (1) RU2741802C2 (fr)
WO (1) WO2017122666A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021007108A1 (fr) * 2019-07-05 2021-01-14 Icahn School Of Medicine At Mount Sinai Méthode de prévention contre la perte de cheveux
US20230416838A1 (en) * 2020-11-16 2023-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
JPWO2024080377A1 (fr) * 2022-10-14 2024-04-18
CN118440198B (zh) * 2024-04-03 2024-11-15 武汉爱博泰克生物科技有限公司 抗人cd69蛋白的兔单克隆抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013665A2 (fr) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Methode permettant de diagnostiquer un cancer du poumon a petites cellules
WO2007019563A2 (fr) 2005-08-09 2007-02-15 University Of Virginia Patent Foundation Methodes et compositions destinees a inhiber la permeabilite vasculaire
JP4777785B2 (ja) * 2006-01-31 2011-09-21 独立行政法人科学技術振興機構 ケモカインレセプターｃｃｒ５のｎ末端領域に対する抗体酵素
US8415372B2 (en) 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
EP2993188B1 (fr) 2009-04-20 2020-08-19 Kyowa Kirin Co., Ltd. Anticorps anti-cd40 comprenant une igg2 ayant trois acide aminés mutés
EP2421899B1 (fr) * 2009-04-23 2016-06-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Anticorps anti-ror1 humain
HUE036392T2 (hu) * 2009-08-07 2018-07-30 Kyowa Hakko Kirin Co Ltd Humanizált anti-amiloid ß oligomer antitest
US9493562B2 (en) * 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
WO2014074847A1 (fr) * 2012-11-09 2014-05-15 The Johns Hopkins University Analyse génétique permettant de déterminer un pronostic chez des patients atteints de la maladie de vaquez
JP6403668B2 (ja) * 2013-05-30 2018-10-10 国立大学法人千葉大学 抗ミオシン調節軽鎖ポリペプチド抗体を含む炎症疾患治療用組成物
ES2898650T3 (es) 2013-06-27 2022-03-08 Univ Monash Proteínas de unión a IL-21 y usos de las mismas
EP3156072B1 (fr) * 2014-06-11 2020-08-19 IDAC Theranostics, Inc. Procédé de réduction des effets secondaires d'un agent de contrôle de point de contrôle immunitaire

Also Published As

Publication number Publication date
KR20180098570A (ko) 2018-09-04
RU2018124601A (ru) 2020-02-14
US10513561B2 (en) 2019-12-24
RU2741802C2 (ru) 2021-01-28
EP3404040A1 (fr) 2018-11-21
US20190002588A1 (en) 2019-01-03
KR102800024B1 (ko) 2025-04-28
AU2017207082A1 (en) 2018-07-05
WO2017122666A1 (fr) 2017-07-20
AU2017207082B2 (en) 2023-07-13
EP3404040B1 (fr) 2022-03-02
BR112018013807A2 (pt) 2018-12-11
IL260083B1 (en) 2023-05-01
CN108431037A (zh) 2018-08-21
JP6872756B2 (ja) 2021-05-19
EP3404040A4 (fr) 2019-08-07
JPWO2017122666A1 (ja) 2018-11-01
CN108431037B (zh) 2021-12-17
ES2913162T3 (es) 2022-05-31
IL260083B2 (en) 2023-09-01
CA3008786A1 (fr) 2017-07-20
MX2018008358A (es) 2018-09-21
IL260083A (en) 2018-07-31
RU2018124601A3 (fr) 2020-04-30

Similar Documents

Publication Publication Date Title
FR21C1030I2 (fr) Conjugué anticorps anti-her2-médicament
EP3423089A4 (fr) Anticorps anti-tigit
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA47268A (fr) Anticorps anti-gpc3
FR25C1022I1 (fr) Anticorps anti-pd-1
EP3334757A4 (fr) Anticorps anti-tigit
EP3297671A4 (fr) Anticorps anti-ror1
DK3625259T3 (da) Anti-sirpalpha-antistoffer
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3498840A4 (fr) Anticorps anti-lag-3
MA46057A (fr) Anticorps anti-ctla4
EP3481869A4 (fr) Anticorps anti-cd73
MA46041A (fr) Anticorps anti-tim -3
EP3387442A4 (fr) Anticorps anti-cd73 humanisés
MA50352A (fr) Anticorps multispécifiques
MA47472A (fr) Anticorps
MA53297A (fr) Anticorps anti-icos
EP3334824A4 (fr) Anticorps anti-pd-1
MA44236A (fr) Anticorps anti-tgfbêta 2
EP3526247A4 (fr) Anticorps anti-il1-rap
DK3606961T3 (da) Garp-tgf-beta-antistoffer
EP3399992A4 (fr) Anticorps autoréticulants
EP3383915A4 (fr) Anticorps anti-pd-1
EP3617231A4 (fr) Anticorps anti-gpc-1